Scott Fettner

718 total citations
16 papers, 570 citations indexed

About

Scott Fettner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Scott Fettner has authored 16 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 5 papers in Immunology. Recurrent topics in Scott Fettner's work include Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Biosimilars and Bioanalytical Methods (3 papers). Scott Fettner is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Biosimilars and Bioanalytical Methods (3 papers). Scott Fettner collaborates with scholars based in United States, Switzerland and United Kingdom. Scott Fettner's co-authors include Ashok Rakhit, Bert L. Lum, Myriam Riek, Marta Hamilton, Michael Pantze, Hannah M. Jones, Xiaoping Zhang, Lucy Rowell, Karen Rittweger and Leon Hooftman and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Scott Fettner

16 papers receiving 557 citations

Peers

Scott Fettner

ONCOL

PRM

IMMUN

RHEUM

Rossana Roncato Italy

Gaëlle Noé France

Brian P. Monahan United States

Mukul Minocha United States

Ting Chan Australia

Myriam Riek Switzerland

Song Ren United States

Jenny Zheng United States

Paul Gougis France

Motohiko Tanaka Japan

Rossana Roncato Italy

Scott Fettner

395 ×1.5

ONCOL

159 ×0.9

PRM

284 ×2.1

77 ×1.1

IMMUN

90 ×1.4

RHEUM

Citations per year, relative to Scott Fettner Scott Fettner (= 1×) peers Rossana Roncato

Countries citing papers authored by Scott Fettner

Since Specialization

Citations

This map shows the geographic impact of Scott Fettner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Fettner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Fettner more than expected).

Fields of papers citing papers by Scott Fettner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Fettner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Fettner. The network helps show where Scott Fettner may publish in the future.

Co-authorship network of co-authors of Scott Fettner

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Fettner. A scholar is included among the top collaborators of Scott Fettner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Fettner. Scott Fettner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Grippo, Joseph F., et al.. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers. Clinical and Translational Science. 14(4). 1524–1534. 6 indexed citations

Fettner, Scott, et al.. (2020). Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 64(5). 39 indexed citations

Fettner, Scott, et al.. (2019). Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector. Expert Opinion on Drug Delivery. 16(5). 551–561. 12 indexed citations

Abdallah, Hisham, Joy Hsu, Peng Lü, et al.. (2016). Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. The Journal of Clinical Pharmacology. 57(4). 459–468. 70 indexed citations

Hamilton, Marta, Julie Wolf, Daniel W. Drolet, et al.. (2014). The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemotherapy and Pharmacology. 73(3). 613–621. 41 indexed citations

Calvert, Hilary, Chris Twelves, Malcolm Ranson, et al.. (2014). Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. Anti-Cancer Drugs. 25(7). 832–840. 11 indexed citations

Zhang, Xiaoping, et al.. (2013). Assessment of disease-drug-drug interaction between single-dose tocilizumab and oral contraceptives in women with active rheumatoid arthritis. International Journal of Clinical Pharmacology and Therapeutics. 52(1). 27–38. 6 indexed citations

Zhang, Xiaoping, et al.. (2013). Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. International Journal of Clinical Pharmacology and Therapeutics. 51(8). 620–630. 21 indexed citations

Zhang, Xiaoping, et al.. (2010). Pharmacokinetic Interaction Study of Ritonavir-Boosted Saquinavir in Combination with Rifabutin in Healthy Subjects. Antimicrobial Agents and Chemotherapy. 55(2). 680–687. 8 indexed citations

10.

Twelves, Chris, José Trigo, Robert H. Jones, et al.. (2008). Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study. European Journal of Cancer. 44(3). 419–426. 37 indexed citations

11.

Fettner, Scott, et al.. (2008). Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anti-Cancer Drugs. 19(2). 209–216. 77 indexed citations

12.

Rakhit, Ashok, Michael Pantze, Scott Fettner, et al.. (2007). The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition. European Journal of Clinical Pharmacology. 64(1). 31–41. 108 indexed citations

13.

Hanauske, Axel‐R., Jim Cassidy, Javier Sastre, et al.. (2007). Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research. 13(2). 523–531. 19 indexed citations

14.

Talpaz, Moshe, Ashok Rakhit, Karen Rittweger, et al.. (2005). Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia. Clinical Cancer Research. 11(17). 6247–6255. 26 indexed citations

15.

Motzer, Robert J., Ashok Rakhit, Michelle S. Ginsberg, et al.. (2001). Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology. 19(5). 1312–1319. 73 indexed citations

16.

Pai, Sudhakar M., Scott Fettner, Gerald Hajian, Mitchell N. Cayen, & Vijay Batra. (1996). Characterization of AUCs from sparsely sampled populations in toxicology studies.. Pharmaceutical Research. 13(9). 1283–1290. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact